99mTc(I)/Re(I) tricarbonyl complexes for in vivo targeting of melanotic melanoma: Synthesis and biological evaluation

European Journal of Medicinal Chemistry

Volumn 50, Issue , 2012, Pages 350-360

  Moura, Carolina ^a   Gano, Lurdes ^a   Mendes, Filipa ^a   Raposinho, Paula D ^a   Abrantes, A M ^b   Botelho, M F ^b   Santos, Isabel ^a   Paulo, António ^a  

^a INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Melanin; Melanoma; Radiopharmaceuticals; Rhenium; Technetium 99m

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; CHELATING AGENT; HALOPERIDOL; MELANIN; MERCAPTAMINE; RHENIUM TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; RHENIUM; SIGMA OPIATE RECEPTOR; TECHNETIUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; COMPLEX FORMATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; EVALUATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPOPHILICITY; MELANOMA; MOLECULAR PROBE; MOLECULAR SIZE; MOUSE; NONHUMAN; TUMOR CELL; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; EXPERIMENTAL MELANOMA; METABOLISM; SKIN TUMOR; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; RHENIUM; SKIN NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84858449323     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.02.014     Document Type: Article

References (42)

1. S.J. Divito, and L.K. Ferris Advances and short comings in the early diagnosis of melanoma Melanoma Res. 20 2010 450 458
2. A.L. Dancey, B.S. Mahon, and S.S. Rayatt A review of diagnostic imaging in melanoma J. Plast. Reconstr. Aesthet. Surg. 61 2008 1275 1283
3. W.D.J. Holder, R.L.J. White, J.H. Zuger, E.J.J. Easton, and F.L. Greene Effectiveness of positron emission tomography for the detection of melanoma metastases Ann. Surg. 227 1998 764 771
4. B. Krug, A.S. Pirson, R. Crott, and T. Vander Borght The diagnostic accuracy of F-18-FDG PET in cutaneous malignant melanoma Eur. J. Nucl. Med. Mol. Imaging 37 2010 1434 1435
5. 18F]N-(2-(Diethylamino) ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance J. Med. Chem. 52 2009 5299 5302
6. R. Larisch, K.W. Schulte, H. Vosberg, T. Ruzicka, and H.W. Muller-Gartner Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo J. Nucl. Med. 39 1998 996 1001
7. 2)), an imaging agent for melanoma staging: relation to pigmentation Nucl. Med. Biol. 32 2005 451 458
8. J.M. Michelot, M.F.C. Moreau, P.G. Labarre, J.C. Madelmont, A.J. Veyre, J.M. Papon, D.F. Parry, J.F. Bonafous, J.Y.P. Boire, G.G. Desplanches, S.J. Bertrand, and G. Meyniel Synthesis and evaluation of new I-125 radiopharmaceuticals as potential tracers for malignant-melanoma J. Nucl. Med. 32 1991 1573 1580
9. J.M. Michelot, M.F.C. Moreau, A.J. Veyre, J.F. Bonafous, F.J. Bacin, J.C. Madelmont, F. Bussiere, P.A. Souteyrand, L.P. Mauclaire, F.M. Chossat, J.M. Papon, P.G. Labarre, P. Kauffmann, and R.J. Plagne Phase-II Scintigraphic clinical-trial of malignant-melanoma and metastases with Iodine-123-N-(2- diethylaminoethyl 4-Iodobenzamide) J. Nucl. Med. 34 1993 1260 1266
10. N. Moins, J. Papon, H. Seguin, D. Gardette, M.F. Moreau, P. Labarre, M. Bayle, J. Michelot, J.C. Gramain, J.C. Madelmont, and A. Veyre Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents Nucl. Med. Biol. 28 2001 799 808
11. A. Mohammed, C. Nicholl, U. Titsch, and M. Eisenhut Radioiodinated N-(alkylaminoalkyl)-substituted 4-methoxy-, 4-hydroxy-, and 4-aminobenzamides: biological investigations for the improvement of melanoma-imaging agents Nucl. Med. Biol. 24 1997 373 380
12. 3] mimicking benzamides for malignant melanoma targeting Nucl. Med. Biol. 37 2010 255 264
13. N. Moins, M. D'Incan, J. Bonafous, F. Bacin, P. Labarre, M.F. Moreau, D. Mestas, E. Noirault, F. Chossat, E. Berthommier, J. Papon, M. Bayle, P. Souteyrand, J.C. Madelmont, and A. Veyre I-123-N-(2-diethylaminoethyl)-2- iodobenzamide: a potential imaging agent for cutaneous melanoma staging Eur. J. Nucl. Med. Mol. Imaging 29 2002 1478 1484
14. F. Chehade, C. de Labriolle-Vaylet, N. Moins, M.F. Moreau, J. Papon, P. Labarre, P. Galle, A. Veyre, and E. Hindie Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I-BZA and C-14-I-BZA J. Nucl. Med. 46 2005 1701 1706
15. C.S. John, W.D. Bowen, T. Saga, S. Kinuya, B.J. Vilner, J. Baumgold, C.H. Paik, R.C. Reba, R.D. Neumann, V.M. Varma, and J.G. McAfee A malignant-melanoma imaging agent - synthesis, characterization, in-vitro binding and biodistribution of Iodine-125-(2-Piperidinylaminoethyl)4-Iodobenzamide J. Nucl. Med. 34 1993 2169 2175
16. P. Labarre, J. Papon, M.F. Moreau, N. Moins, M. Bayle, A. Veyre, and J.C. Madelmont Melanin affinity of N-(2-diethylaminoethyl)-4-lodobenzamide, an effective melanoma imaging agent Melanoma Res. 12 2002 115 121
17. M. Wolf, U. Bauder-Wust, U. Haberkorn, W. Mier, and M. Eisenhut Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pH and DNA interaction Melanoma Res. 15 2005 383 391
18. M. Wolf, U. Bauder-Wust, A. Mohammed, F. Schonsiegel, W. Mier, U. Haberkorn, and M. Eisenhut Alkylating berizamides with melanoma cytotoxicity Melanoma Res. 14 2004 353 360
19. 2: a potential small-molecule single-photon emission computed tomography probe for imaging metastatic melanoma Cancer Res. 65 2005 4979 4986
20. P. Auzeloux, M.F. Moreau, J. Papon, M. Bayle, M. Borel, R. Pasqualini, and J.C. Madelmont Technetium-99m radiolabelling of an N-amino-alkyl-benzamide nitrido- and oxo-technetium bis(aminoethanethiol) derivative synthesis and biological results. Potential melanoma tracer agents J. Label. Compd. Radiopharm. 42 1999 567 579
21. P. Auzeloux, J. Papon, E.M. Azim, M. Borel, R. Pasqualini, A. Veyre, and J.C. Madelmont A potential melanoma tracer: synthesis, radiolabeling, and biodistribution in mice of a new nitridotechnetium bis(aminothiol) derivative pharmacomodulated by a N-(diethylaminoethyl)benzamide J. Med. Chem. 43 2000 190 198
22. P. Auzeloux, J. Papon, T. Masnada, M. Borel, M.F. Moreau, A. Veyre, R. Pasqualini, and J.C. Madelmont Synthesis and biodistribution of technetium-99m-labelled N-(diethylaminoethyl)benzamide via a bis(dithiocarbamate) nitridotechnetium(V) complex J. Label. Compd. Radiopharm. 42 1999 325 335
23. P. Auzeloux, J. Papon, R. Pasqualini, and J.C. Madelmont Synthesis and biodistribution of a new oxo-technetium-99m bis(aminothiol) complex as a potential melanoma tracer J. Med. Chem. 44 2001 1116 1121
24. M. Friebe, A. Mahmood, C. Bolzati, A. Drews, B. Johannsen, M. Eisenhut, D. Kraemer, A. Davison, and A.G. Jones [Tc-99m]oxotechnetium(V) complexes of amine-amide-dithiol chelates with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma J. Med. Chem. 44 2001 3132 3140
25. M. Eisenhut, A. Mohammed, W. Mier, F. Schonsiegel, M. Friebe, A. Mahmood, A.G. Jones, and U. Haberkorn Melanoma uptake of Tc-99m complexes containing the N-(2-diethylaminoethyl)benzamide structural element J. Med. Chem. 45 2002 5802 5805
26. M. Friebe, A. Mahmood, H. Spies, R. Berger, B. Johannsen, A. Mohammed, M. Eisenhut, C. Bolzati, A. Davison, and A.G. Jones '3+1' mixed-ligand oxotechnetium(V) complexes with affinity for melanoma: synthesis and evaluation in vitro and in vivo J. Med. Chem. 43 2000 2745 2752
27. P.I. Rey, M. Papadopoulos, J. Giglio, E. Leon, F. Schreiber, A. Paolino, R. Fernandez, E. Manta, J. Chabalgoity, and A. Leon Oxotechnetium and Oxorhenium 3+1 mixed ligand complexes as potential melanoma targeting agents World J. Nucl. Med. 4 2005 111 119
28. 99mTc) complexes functionalized with melanin-binding pharmacophores New J. Chem. 34 2010 2564 2578
29. 99mTc(I)/Re(I) tricarbonyl complexes with tridentate cysteamine-based ligands: synthesis, characterization and in vitro/In vivo evaluation Eur. J. Inorg. Chem. 2011 5405 5413
30. C. Fernandes, I.C. Santos, I. Santos, H.J. Pietzsch, J.U. Kunstler, W. Kraus, A. Rey, N. Margaritis, A. Bourkoula, A. Chiotellis, M. Paravatou-Pestsotas, and I. Pirmettis Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a Tc-99m biomarker for EGFR-TK imaging Dalton Trans. 2008 3215 3225
31. 3] (appa = [(5-amino-pentyl)-pyridin-2-yl-methyl- amino]-acetic acid) Nucl. Med. Biol. 30 2003 465 470
32. C. Moura, C. Fernandes, L. Gano, A. Paulo, I.C. Santos, I. Santos, and M.J. Calhorda Influence of the ligand donor atoms on the in vitro stability of rhenium(I) and technetium (I)-99m complexes with pyrazole-containing chelators: experimental and DFT studies J. Organomet. Chem. 694 2009 950 958
33. 99mTc with a multidentate amine oxime Int. J. Appl. Radiat. Isot. 35 1984 467 470
34. T.Q. Pham, P. Berghofer, X. Liu, I. Greguric, B. Dikic, P. Ballantyne, F. Matmer, V. Nguyen, C. Loc'h, and A. Katsifis Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, I-123-MEL037, for malignant melanoma J. Nucl. Med. 48 2007 1348 1356
35. T.Q. Pham, I. Greguric, X. Liu, P. Berghofer, P. Ballantyne, J. Chapman, F. Mattner, B. Dikic, T. Jackson, C. Loc'h, and A. Katsifis Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma J. Med. Chem. 50 2007 3561 3572
36. T. Lee Collier, R.N. Waterhouse, and M. Kassiou Imaging sigma receptors: applications in drug development Current Pharmaceutical Design 2007 Bentham Science Publishers Ltd 51 72
37. E. Aydar, C.P. Palmer, and M.B.A. Djamgoz Sigma receptors and cancer Cancer Res. 64 2004 5029 5035
38. R. Quirion, W.D. Bowen, Y. Itzhak, J.L. Junien, J. Musacchio, R.B. Rothman, S. Tsung-Ping, S.W. Tam, and D.P. Taylor A proposal for the classification of sigma binding sites Trends Pharmacol. Sci. 13 1992 85 86
39. B.J. Vilner, C.S. John, and W.D. Bowen Sigma-1 and Sigma-2 receptors are expressed in a wide variety of human and Rodent tumor cell lines Cancer Res. 55 1995 408 413
40. V. Megalizzi, V. Mathieu, T. Mijatovic, P. Gailly, O. Debeir, N. De Neve, M. Van Damme, G. Bontempi, B. Haibe-Kains, C. Decaestecker, Y. Kondo, R. Kiss, and F. Lefranc 4-IBP, a sigma(1) receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs Neoplasia 9 2007 358 369
41. B. Wang, R. Rouzier, C.T. Albarracin, A. Sahin, P. Wagner, Y. Yang, T.L. Smith, F.M. Bernstam, A.C. Marcelo, G.N. Hortobagyi, and L. Pusztai Expression of sigma 1 receptor in human breast cancer Breast Cancer Res. Treat. 87 2004 205 214
42. 2Br] Inorg. Chem. Commun. 7 2004 1023 1026